2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Molecular genetic profile in BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia can further refine outcome prediction in addition to that by end-induction minimal residual disease detection.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The recently proposed molecular genetic criteria promise improved risk-prediction in B-cell acute lymphoblastic leukemia (B-ALL). This study assesses their utility in BCR-ABL1 negative pediatric B-ALL, particularly with respect to end-induction minimal residual disease (MRD). The DNA was analyzed for copy number alterations in CDKN2A/B, PAX5, IKZF1, and other genes. Seventy-six cases with median age 7 years (2 months-18 years) included MRD-positive (24; 32%), and MRD negative-standard (20; 26%), intermediate (20; 26%), & high risk (12;16%) cases. The risk classification was based on age, initial total leukocyte count, central nervous system involvement, cytogenetics, day 8 prednisolone response and MRD status after induction chemotherapy. The genetic profile based on Moorman's criteria identified two subgroups with different event free survival (EFS) (0.77 vs. 0.38; p = .045) and overall survival (OS) (0.90 vs. 0.30; p = .037) in the MRD-negative intermediate-risk group. The genetic profile also separated two subgroups with different EFS (0.75 vs. 0.41; p = .036) in the MRD-positive group, however the OS was not different (0.75 vs. 0.57; p = .293).

          Related collections

          Author and article information

          Journal
          Leuk Lymphoma
          Leukemia & lymphoma
          Informa UK Limited
          1029-2403
          1026-8022
          August 2018
          : 59
          : 8
          Affiliations
          [1 ] a Laboratory Oncology Unit , Dr BRA IRCH, All India Institute of Medical Sciences (AIIMS) , New Delhi , India.
          [2 ] b Department of Medical Oncology , Dr BRA IRCH, All India Institute of Medical Sciences (AIIMS) , New Delhi , India.
          [3 ] c Division of Epidemiology & Biostatistics , National Institute of Epidemiology , Chennai , India.
          Article
          10.1080/10428194.2017.1408087
          29199525
          ce712de5-6ba5-4cf2-95e1-1c365bc983df
          History

          B-ALL genetics,MRD in B-ALL,minimal residual disease in ALL,molecular genetics in acute leukemia

          Comments

          Comment on this article